Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis ; volume:17 ; number:1 ; day:10 ; month:9 ; year:2019 ; pages:1-10 ; date:12.2019
Pediatric rheumatology ; 17, Heft 1 (10.9.2019), 1-10, 12.2019
- Creator
-
Khraishi, Majed
Millson, Brad
Woolcott, John
Jones, Heather
Marshall, Lisa
Ruperto, Nicolino
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-019-0358-x
- URN
-
urn:nbn:de:101:1-2020012501104741323451
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Khraishi, Majed
- Millson, Brad
- Woolcott, John
- Jones, Heather
- Marshall, Lisa
- Ruperto, Nicolino
- SpringerLink (Online service)
Other Objects (12)
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Predictors of response to methotrexate in juvenile idiopathic arthritis
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Predictors of response to methotrexate in juvenile idiopathic arthritis
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Predictors of response to methotrexate in juvenile idiopathic arthritis
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis